Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax with Enzalutamide in mCRPC
NCT03751436Phase 1Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Aug 2019
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of venetoclax in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoints: Maximum Tolerated Dose at 28 days, Recommended Phase 2 Dose at 28 days and 1 more. Started Aug 2019; status: completed.
02
Drugs
venetoclax
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03751436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03751436.